6 Best Peptides for Fatty Liver (NAFLD)

What to Know Before Choosing a Peptide for Fatty Liver (NAFLD)

The peptide landscape for fatty liver disease is unusually wide. On one end you have semaglutide, which in August 2025 became the first peptide drug to receive FDA approval specifically for metabolic dysfunction-associated steatohepatitis (MASH), the inflammatory advanced stage of NAFLD. On the other end you have compounds like BPC-157 and MOTS-c, which show up constantly in peptide community protocols for liver health but have no published human clinical trial data for this specific condition. Both ends of that spectrum belong in this guide.

A compound earns a slot here because people use it, or are actively discussing using it, for fatty liver disease. That is the whole test. FDA-approved drugs, telemedicine-prescribed peptides, and research-only compounds are all eligible. Evidence strength shapes how honestly each entry describes the state of the science. It never determines whether a compound appears on the list. A compound with only community-reported use belongs here, with that thin evidence stated plainly rather than omitted.

The compounds are numbered by how prominently each appears in the research literature and in real-world use for NAFLD. That order gives the list a logical spine. It is not a ranking, and number one is not the right compound for everyone. Number six is not inferior to number two. The right peptide for a specific person depends on their health history, their current metabolic picture, and a conversation with a qualified clinician. This article gives you the map of the field. Turning that map into a personalized plan is what the MyPeptidePal app is built to do.

1. Semaglutide: The Only Peptide with a Specific Liver Disease Approval

Semaglutide is a GLP-1 receptor agonist, a peptide that mimics the glucagon-like peptide-1 hormone your gut naturally releases after eating. That hormone signals the pancreas to release insulin, reduces appetite, and activates a metabolic cascade inside liver cells that turns down fat production and turns up fat burning. GLP-1 receptors are significantly downregulated in NAFLD, especially in the more advanced inflammatory stages, which is part of why activating those receptors produces such pronounced effects in people with this condition.

In a 72-week randomized controlled trial published in the New England Journal of Medicine in 2021, semaglutide produced NASH resolution in 59 percent of participants compared to 17 percent on placebo, without worsening liver fibrosis. That remains the most cited landmark result for any peptide in the NAFLD field. A systematic review of 24 clinical trials involving more than 6,000 participants confirmed that GLP-1 receptor agonists as a class improve hepatic steatosis, inflammation, and fibrosis, with semaglutide as the most frequently studied agent across the entire trial landscape.

In August 2025, the FDA approved semaglutide specifically for adults with moderate to advanced liver fibrosis due to MASH, making it the first peptide drug to carry a liver-specific indication. Off-label use for NAFLD had been common for years before that approval, supported by the Phase 2 data and by consistent real-world reports of normalized liver enzymes, reduced liver size on ultrasound, and fibrosis reversal confirmed on follow-up biopsy. The compound is prescribed through standard medical and telemedicine channels for qualifying patients.

The side effect profile is well-characterized. Nausea, vomiting, and diarrhea are the most common complaints, particularly during dose escalation, and they typically lessen over time. The compound is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2 syndrome, and in those with a history of pancreatitis or elevated pancreatitis risk. The evidence base here is as strong as the NAFLD peptide field offers: multiple randomized controlled trials, biopsy-confirmed histological endpoints, a systematic review across thousands of participants, and a specific FDA approval. For NAFLD, semaglutide carries the most robust clinical support of any peptide available as of 2026.

2. Tirzepatide: Dual-Action Agonist for Liver Fat Reduction

Tirzepatide adds a second receptor pathway to the mechanism that semaglutide operates through. It is a single peptide molecule that binds both the GLP-1 receptor and the GIP receptor simultaneously. The GLP-1 component suppresses hepatic fat production and reduces oxidative stress in liver cells. The GIP component raises energy expenditure and directly stimulates the breakdown of stored fat. Both receptor pathways elevate cyclic AMP inside liver cells, which activates AMPK, the enzyme that functions as the metabolic switch between fat storage and fat burning. Acting on two receptors at once produces more potent inhibition of liver fat accumulation than a single receptor agonist achieves.

Tirzepatide is FDA-approved for type 2 diabetes and obesity and is widely prescribed through telemedicine platforms for qualifying patients. It does not yet carry a specific approval for NAFLD or MASH as of mid-2026, though the SYNERGY-OUTCOMES Phase 2 trial is actively evaluating it for prevention of major adverse liver outcomes in high-risk metabolic liver disease. Existing randomized controlled trial data shows up to an 8 percent absolute reduction in liver fat measured by imaging, and recent trial data documents significant fibrosis reduction and improved liver histology in fatty liver patients.

Real-world reports are consistent and striking. Users have reported NAFLD reversal confirmed by ultrasound and normalized liver enzymes within three to six months, along with liver size reductions of several centimeters and resolution of comorbidities including insulin resistance. The pattern across community reports suggests tirzepatide produces rapid liver changes for many users, though no direct head-to-head comparison with semaglutide for liver-specific outcomes has been published.

The side effect profile closely mirrors semaglutide's, given that both compounds share the GLP-1 receptor component. GI side effects predominate, and the same contraindications apply around thyroid cancer history, MEN 2 syndrome, and pancreatitis. One safety note for this entire compound class: unapproved, unregulated research peptide products labeled as the related investigational compound retatrutide have been linked to cases of acute liver toxicity in Australia as of January 2026. That warning applies to unregulated black-market products, not to prescribed tirzepatide from licensed pharmacies, but it is a clear illustration of why regulatory status and sourcing matter significantly when working with this class.

3. Liraglutide: The Established GLP-1 Option with Biopsy-Confirmed Data

Liraglutide was the GLP-1 receptor agonist that established the class proof of concept for NAFLD before semaglutide became the dominant agent in the field. It works through the same receptor pathway and the same downstream AMPK-mediated mechanism, and it was evaluated in the LEAN trial, a randomized controlled trial that demonstrated higher NASH resolution and lower fibrosis progression compared to placebo. The LEAN trial gave liver medicine its first biopsy-confirmed evidence that a GLP-1 agonist could meaningfully improve liver histology in NASH patients, independent of weight loss alone.

Liraglutide is FDA-approved for type 2 diabetes and obesity and is available by prescription. It is the second most studied GLP-1 receptor agonist in NAFLD clinical trials after semaglutide, a distinction earned through real evidence. The main practical difference for a patient considering this class is scheduling: liraglutide requires a daily injection while semaglutide is once weekly. For liver-specific outcomes, available evidence suggests semaglutide produces stronger results, but liraglutide remains a clinically viable option, particularly for patients already established on it for another indication whose physician prefers continuity over switching agents.

The safety profile is essentially the same as the rest of the GLP-1 class. GI side effects are the primary complaint during dose escalation. The same contraindications around medullary thyroid cancer history, MEN 2, and pancreatitis apply. Liraglutide has been in clinical use longer than the newer agents, giving it a broader real-world safety record, though tirzepatide and semaglutide have accumulated substantial post-approval safety data of their own. For anyone looking specifically at GLP-1 agonists for liver outcomes supported by biopsy data, liraglutide belongs squarely in the conversation.

4. BPC-157: Cytoprotective Research Peptide with Animal Data for the Liver

BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in gastric juice. It has developed a substantial following in peptide research communities for tissue repair, gut healing, and injury recovery, and liver health has become one of the areas where it is regularly discussed. The mechanism proposed for liver applications centers on its cytoprotective and angiogenic properties. It appears to promote the formation of new blood vessels in damaged tissue and to exert protective effects on gut and hepatic cells, partly through modulation of nitric oxide signaling and upregulation of growth hormone receptors.

No human clinical trial data has been published for BPC-157 in fatty liver disease as of 2026. Animal model research has shown that it can prevent liver necrosis and fatty changes under experimental conditions, and those findings drive the community discussion of it in the liver health context. The specific molecular pathways most central to NAFLD, including the ACC1 and SREBP-1c lipogenesis machinery that GLP-1 agonists target directly, are not well characterized for BPC-157. The community interest is real and the animal data exists, but anyone using BPC-157 for fatty liver is operating well outside the clinical evidence base.

BPC-157 is sold as a research chemical and is not FDA-approved for any indication. It is not available through standard medical or telemedicine prescription channels for this use. Users in peptide communities report injection site discomfort and occasional GI distress as the most common side effects, but the formal safety profile for long-term human use is genuinely unknown. There are no validated human dosing protocols for NAFLD in any clinical setting. The AMA and mainstream medical authorities have issued broad warnings about unregulated injectable peptides covering contamination, mislabeling, and unknown drug interactions, and those warnings apply here. This is a compound worth knowing about because people actively use and discuss it for liver health. The evidence supporting that use is preclinical, and the safety picture is incomplete.

5. MOTS-c: Mitochondrial Peptide with Mechanistic Overlap and Limited Liver Data

MOTS-c is a mitochondrial-derived peptide, meaning it is encoded within the mitochondrial genome rather than the nuclear genome, which makes it biologically unusual among the compounds in this field. Identified in 2015 as a hormone-like signaling molecule that mitochondria secrete into circulation under metabolic stress, its primary studied action is activation of AMPK, the same central metabolic switch that GLP-1 receptor agonists activate through a completely different upstream pathway. MOTS-c reaches that AMPK activation by inhibiting the folate cycle and increasing a metabolite called AICAR, which in turn activates AMPK directly. The downstream effects, suppression of de novo fat synthesis and promotion of fatty acid oxidation, overlap substantially with the mechanism that makes GLP-1 agonists effective for fatty liver.

That mechanistic overlap is the main reason MOTS-c generates discussion in the NAFLD context. The reasoning is straightforward: if AMPK activation is the core event responsible for reducing liver fat, and MOTS-c activates AMPK through a distinct pathway, then MOTS-c may produce similar hepatic benefits. Animal studies and early human research have confirmed that MOTS-c improves insulin sensitivity, reduces fat accumulation, and carries anti-inflammatory properties. What does not yet exist is clinical trial data specific to NAFLD. No published Phase 2 or Phase 3 trial has evaluated MOTS-c for liver fat reduction in humans, and the extrapolation from its metabolic mechanism to a NAFLD indication remains theoretical as of 2026.

MOTS-c is sold as a research chemical and is not available through any prescription or telemedicine channel for liver disease. It is used in biohacker and peptide community protocols primarily for metabolic health and longevity goals, with NAFLD-adjacent conditions like insulin resistance and metabolic syndrome often part of the stated rationale. Formal human safety data is sparse, and long-term effects have not been characterized. The compound is mechanistically compelling for anyone thinking seriously about liver fat biology, but the current honest characterization is that it is a preclinical candidate with a strong theoretical rationale rather than a clinically validated option for NAFLD.

6. Ovagen: Peptide Bioregulator Targeting Hepatocyte Function

Ovagen, also known in some formulations as Hepatamine, is a short-chain peptide bioregulator developed within the Russian peptide bioregulator tradition associated with Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. Peptide bioregulators in this system are derived from specific organ tissues and are theorized to act as gene expression modulators, binding to DNA and RNA in a tissue-specific manner to influence the transcription of organ-relevant proteins. Ovagen is derived from liver tissue and is proposed to support hepatocyte regeneration, reduce oxidative stress within liver cells, and normalize the production of liver enzymes.

The honest characterization of the evidence for Ovagen in NAFLD is that peer-reviewed human clinical trial data is very limited in the Western research literature, and no controlled NAFLD trial for this compound exists in the major Western trial databases. Peptide bioregulators have been used for decades in Russian and Eastern European clinical practice in organ-specific cytoprotection contexts, and practitioners in that tradition report hepatoprotective benefits. From a Western clinical evidence standpoint, Ovagen in NAFLD sits in the experiential and theoretical category.

Ovagen is available as an oral supplement in enteric-coated capsule form, making it one of the few liver-focused peptide options in this guide that does not require injection. It is sold through specialty peptide bioregulator retailers and some European suppliers without a prescription in most markets where it is available. It is not FDA-approved for any therapeutic indication. The tolerability reported in bioregulator literature is generally good, with no serious adverse events prominently reported, but formal clinical safety studies are sparse. For anyone following the broader peptide bioregulator tradition, Ovagen is the liver-specific entry point in that system, and its inclusion here reflects genuine active use and discussion in that community for hepatic support.

How These Peptides Compare

Frequently Asked Questions

Is semaglutide actually approved specifically for fatty liver disease?

Yes. In August 2025, the FDA approved semaglutide specifically for adults with moderate to advanced liver fibrosis caused by metabolic dysfunction-associated steatohepatitis (MASH), the inflammatory advanced stage of NAFLD. This is a distinct liver-specific indication, separate from its earlier approvals for type 2 diabetes and obesity. The approval was supported by biopsy-confirmed trial data showing NASH resolution in 59 percent of participants at 72 weeks compared to 17 percent on placebo.

Can research peptides like BPC-157 or MOTS-c actually reverse fatty liver?

There is no human clinical trial data supporting BPC-157 or MOTS-c for fatty liver reversal as of 2026. BPC-157 has animal model data showing liver-protective effects, and MOTS-c has a mechanistic rationale based on its AMPK activation, which is the same pathway the GLP-1 drugs use. People do use both compounds in community protocols for liver health and report positive experiences, but those reports are anecdotal and uncontrolled. The contrast with semaglutide, which has biopsy-confirmed trial data, is significant.

Do you need a prescription to access these compounds?

The GLP-1 receptor agonists, semaglutide, tirzepatide, and liraglutide, require a prescription and are available through standard medical channels and telemedicine platforms for qualifying patients. BPC-157, MOTS-c, and Ovagen do not require a prescription and are sold as research chemicals or dietary supplements depending on jurisdiction, but they are not FDA-approved for any therapeutic indication and lack the regulatory oversight that applies to prescription drugs.

Are there meaningful safety differences across these compounds?

The safety profile varies significantly across this list. The GLP-1 agonists have well-characterized safety data from large clinical trials: GI side effects are common during dose escalation, and there are specific contraindications around thyroid cancer history and pancreatitis risk. Unregulated research peptides like BPC-157 and MOTS-c carry different and less well-defined risks, including contamination, mislabeling, and unknown drug interactions, because they are produced outside the regulatory frameworks that govern pharmaceutical manufacturing. The medical community has issued broad warnings about injectable peptides from unregulated sources because quality and safety cannot be independently verified.

How long does it take for peptides to show results for fatty liver?

The clinical trial data and real-world reports both suggest measurable changes in liver enzymes within weeks of starting a GLP-1 agonist, but normalization of enzymes and reversal of fibrosis typically takes months to a year or more. A pattern that recurs in community reports is that liver markers take longer to fully normalize than other metabolic markers like blood sugar or cholesterol. The honest answer is that meaningful liver improvement is a months-long process, and biopsy-confirmed fibrosis reversal may take a year or longer even with a consistent and favorable response.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for fatty liver (NAFLD) in one place.